MAIN CONTENT
A nomination withdrawn before the committee vote
Reuters and the Associated Press reported that the White House withdrew Overton's nomination as prospects for clearing the Senate Health, Education, Labor and Pensions Committee deteriorated. The committee was scheduled to vote on Wednesday, November 18. Its Republican chairman, physician Bill Cassidy of Louisiana, publicly said he had not decided whether to support her. Crucially, Overton was not voted down by the committee: the withdrawal came before the planned ballot. That distinction matters when assessing what the Senate actually decided.
Trump selected Overton in August after the FDA had been without a Senate-confirmed commissioner since May. As deputy director of the White House Domestic Policy Council, she had been involved in important health initiatives. Yet relevant medical credentials and government experience did not settle the fundamental concern of lawmakers: could an official closely associated with the administration's agenda demonstrate independent judgment in disputes where scientific evidence and political messaging collide?
Vaccination policy becomes a test of scientific trust
Childhood immunization emerged as a particularly sensitive fault line. Cassidy questioned Overton's role in proposals to revise the vaccination schedule, space out doses and separate the combined measles, mumps and rubella vaccine, known as MMR.
















